2024-11-23 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Analysis Report

**1. Performance Comparison & Alpha/Beta Analysis:**

UnitedHealth Group Inc. (UNH) is a diversified healthcare company providing a range of healthcare products and services.

The cumulative return of UNH (201.96%) significantly outperformed the S&P 500 (VOO) cumulative return (127.58%) by 74.38%.  This places UNH at the 46.97th percentile of its historical relative performance against the S&P 500, based on the provided data's maximum and minimum historical divergence.

| Year       | CAGR     | MDD (%) | Alpha | Beta | Cap (B) |
|------------|----------|---------|-------|------|---------|
| 2015-2017  | 129.6%   | 12.2%   | 91.2% | 0.9  | 202.9   |
| 2016-2018  | 123.9%   | 18.6%   | 91.6% | 0.9  | 229.3   |
| 2017-2019  | 90.5%    | 21.0%   | 38.8% | 0.9  | 270.6   |
| 2018-2020  | 66.1%    | 35.3%   | 18.8% | 1.1  | 322.7   |
| 2019-2021  | 116.2%   | 35.3%   | 16.1% | 1.0  | 462.1   |
| 2020-2022  | 89.2%    | 35.3%   | 65.6% | 0.9  | 487.9   |
| 2021-2023  | 57.0%    | 16.3%   | 22.1% | 0.5  | 484.5   |
| 2022-2024  | 22.3%    | 18.8%   | -7.7% | 0.5  | 549.9   |

**Analysis:**  UNH consistently demonstrates high CAGR (Compound Annual Growth Rate) over the analyzed periods, indicating strong historical performance.  The Alpha values generally suggest outperformance relative to the market (except for the most recent period), while the Beta values, mostly around 0.9, indicate a relatively similar level of volatility to the overall market.  Note that the Alpha values presented seem unusually high and may represent a different calculation than standard alpha.  The MDD (Maximum Drawdown) values highlight periods of significant price decline.


**2. Recent Price Movement:**

* **Last Closing Price:** $590.78
* **5-day Moving Average:** $591.08
* **20-day Moving Average:** $587.59
* **60-day Moving Average:** $584.33

**Analysis:** The price is slightly below its 5-day moving average, suggesting a minor short-term downward trend. However, it remains above both the 20-day and 60-day moving averages, indicating a positive longer-term trend.


**3. Technical Indicators & Expected Return:**

* **RSI:** 61.08 (Slightly above neutral; not overbought)
* **PPO:** -0.07 (Slightly negative; suggesting a weak momentum)
* **20-Day Relative Divergence Change:** +4.11 (Positive, indicating short-term upward momentum)
* **Expected Return (Long-Term):** 36.54% (Significant outperformance of the S&P 500 over the long term (2+ years), assuming consistent historical trend.)

**Analysis:** The technical indicators present a mixed picture. While the RSI suggests no overbought condition, the negative PPO indicates weak momentum. The positive relative divergence suggests a potential short-term uptrend. The high expected return warrants further investigation into the model used to derive this value.  The current price is not exceptionally high, thereby not indicating an immediate sharp reversal.

**4. Recent Financial Performance:**

| Date       | EPS      | Revenue (B$) |
|------------|----------|---------------|
| 2024-11-04 | 6.56     | 100.82        |
| 2024-08-09 | 4.58     | 98.86         |
| 2024-05-09 | -1.53    | 99.80         |
| 2023-11-06 | 6.31     | 92.36         |
| 2024-11-04 | 6.31     | 92.36         | *(Duplicate entry)*


**Analysis:** Revenue remains consistently high.  The EPS shows significant fluctuation, with a notable loss in Q2 2024.  Further analysis is needed to understand the causes of this fluctuation.  The duplication of the 2024-11-04 data needs clarification. Comparison with analyst estimates for the most recent quarter is necessary for a complete picture.

**6. Financial Statements (Quarterly Data):**

**1) Revenue and Profitability:**

| Quarter     | Revenue (B$) | Profit Margin (%) |
|-------------|---------------|--------------------|
| 2024-09-30  | $99.18       | 21.56             |
| 2024-06-30  | $97.86       | 21.52             |
| 2024-03-31  | $98.78       | 22.26             |
| 2023-12-31  | $93.25       | 22.33             |
| 2023-09-30  | $91.36       | 24.51             |

**2) Capital and Profitability:**

| Quarter     | Equity (B$) | ROE (%) |
|-------------|--------------|---------|
| 2024-09-30  | $94.53       | 6.41    |
| 2024-06-30  | $89.36       | 4.72    |
| 2024-03-31  | $86.69       | -1.63   |
| 2023-12-31  | $88.76       | 6.15    |
| 2023-09-30  | $84.49       | 6.91    |

**Analysis:**  Revenue remains relatively stable and high. Profit margins are healthy but show some recent decline.  The ROE (Return on Equity) is positive in most quarters but shows negative value in Q1 2024.  This needs further investigation.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  I cannot provide this information directly.)*  Please conduct your own research on recent earnings news, analyst opinions, and market outlook for UNH using these sources.  Look for news regarding the Q2 2024 loss, and the recent performance of the stock.

**8. Overall Analysis:**

UNH has shown strong historical performance, significantly outperforming the S&P 500.  However, recent financial results show some concerning indicators (Q2 2024 loss and fluctuations in EPS and ROE).  The mixed technical indicators suggest uncertainty in the short-term, while the long-term outlook appears positive based on historical data and a high projected return (although this needs further verification).  Thorough review of recent news and analyst opinions, along with a deeper analysis of the Q2 2024 earnings report, is crucial before making any investment decisions.  The unusually high alpha values should be further investigated.

**9. Disclaimer:** This analysis is based on the limited data provided and should not be considered financial advice.  Conduct thorough due diligence and consult with a financial advisor before making any investment decisions.
